Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease

Journal of the Neurological Sciences

Volumn 208, Issue 1-2, 2003, Pages 9-15

  Kato, Hiroyuki ^a,b   Araki, Tsutomu ^c   Imai, Yutaka ^c   Takahashi, Akira ^b   Itoyama, Yasuto ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Astrocytes; Dopamine; Mice; MPTP; Neuroprotection; ONO 2506; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ARUNDIC ACID; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROPROTECTIVE AGENT; OCTANOIC ACID DERIVATIVE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0345118197     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00411-2     Document Type: Article

References (27)

1. Araki T., Kumagai T., Tanaka K., Matsubara M., Kato H., Itoyama Y.et al. Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res. 918:2001;176-181.
2. Brightman M. Implication of astroglia in the blood-brain barrier. Ann. N.Y. Acad. Sci. 633:1991;343-347.
3. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80:1983;4546-4550.
4. Francis J.W., von Visger J., Markelonis G.J., Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17:1995;7-12.
5. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
6. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:1984;467-469.
7. Gluck M.R., Krueger M.J., Ramsey R.R., Sabin S.O., Singer T.P., Nicklas W.J. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridium and 4-phenylpyridine analogs in inner membrane preparation. J. Biol. Chem. 269:1994;3167-3174.
8. Kagamiishi Y., Tateishi N., Shintaku K., Satoh S., Katsumata S., Shinagawa R.et al. Ameliorative effects of ONO-2506 on brain damage following the transient ischemia in rats. Abstr. Soc. Neurosci. 24:1998;984.
9. Kato H., Kogure K., Araki T., Itoyama Y. Astroglial and microglial reactions in the gerbil hippocampus with induced ischemic tolerance. Brain Res. 664:1994;69-76.
10. A receptor disappearance in cultures astrocytes and ischemic brain. Abstr. Soc. Neurosci. 25:1999;2108.
11. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
12. Matsui T., Tateishi N., Kagamiishi Y., Satoh S., Kondo K., Morioka E.et al. Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral artery in rats. Abstr. Soc. Neurosci. 24:1998;254.
13. Nawashiro H., Brenner M., Fukui S., Shimada K., Hallenbeck J.M. High susceptibility to cerebral ischemia in GFAP-null mice. J. Cereb. Blood Flow Metab. 20:2000;1040-1044.
14. Nicholls D., Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 11:1990;462-468.
15. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
16. O'Callaghan J.P., Miller D.B., Reinhard J.F. Jr. Characterization of the origins of astrocyte response to injury using the 1-methyl-4-phenyl-1,2,3,6-tetrahtdropyridine. Brain Res. 521:1990;3-80.
17. Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20:1997;507-577.
18. Shimoda T., Tateishi N., Shintaku K., Yada N., Katagi J., Akiyama T.et al. ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Abstr. Soc. Neurosci. 24:1998;984.
19. Shinagawa R., Tateishi N., Shimoda T., Shintaku K., Yada N., Honjo K.et al. ONO-2506 ameliorates neurodegeneration through inhibition of reduction of GLT-1 expression. Abstr. Soc. Neurosci. 24:1998;984.
20. Shinagawa R., Tateishi N., Shimoda T., Maekawa H., Yada N., Akiyama T.et al. Modulating effects of ONO-2506 on astrocytic activation in cultured astrocytes from rat cerebrum. Abstr. Soc. Neurosci. 25:1999;2108.
21. Shintaku K., Tateishi N., Kagamiishi Y., Sato S., Katsumata S., Nakayama Y.et al. Ameliorative effects of ONO-2506 on neurological deficits and infarction after transient MCA occlusion in rats: studying of therapeutic time window. Abstr. Soc. Neurosci. 25:1999;2108.
22. Tanaka S., Suzuki K., Watanabe M., Matsuda A., Tone S., Koike T. Upregulation of a new microglial gene, mrf-1, in response to programmed neuronal cell death and degeneration. J. Neurosci. 18:1998;6358-6369.
23. Tanji H., Araki T., Nagasawa H., Itoyama Y. Differential vulnerability of dopamine receptors in the mouse brain treated by MPTP. Brain Res. 824:1999;224-231.
24. Tateishi N., Mori T., Kagamiishi Y., Satoh S., Katsube N., Morikawa E.et al. Astrocytic activation and delayed infarct expansion following permanent focal ischemia in rats: Part II. Suppression of astrocytic activation by a novel agent (R)-(-)-2propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurological deficits. J. Cereb. Blood Flow Metab. 22:2002;723-734.
25. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
26. Walz W. Role of glial cells in the regulation of the brain ion microenvironment. Prog. Neurobiol. 33:1989;309-333.
27. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C.et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771.